Abstract

To determine the influence of clinical and angiographic variables, including the anatomic disease pattern, on the outcome of iliac stent placement. The 455 patients of the study population were divided in three groups according to the anatomic distribution of their peripheral atherosclerosis lesions. Pattern type 1 (focal aortoiliac and/or common iliac lesion) included 180 patients (39.6%), type 2 (external iliac lesion) comprised 58 patients (12.8%), and type 3 (multilevel lesions) included 217 patients (47.7%). Complete relief of symptoms immediately after revascularization was observed in 88.3% and 85.4% of patients with pattern type 1 and 2, respectively, compared to 60.1% with type 3 (P < .05). The persistence of clinical benefit at 36-month follow-up was 91.6%, 97.9%, and 60.8% in disease patterns 1, 2, and 3, respectively. The overall 1-year mortality rate was 3% with type 1 lesions, 5.7% with type 2, and 9.7% with type 3. On multivariate logistic regression, the presence of a disease pattern type 3 was the most powerful indicator (P < .001) of early unsatisfactory clinical outcome in iliac stent placement. Unexpectedly, female gender was predictive of unsatisfactory clinical outcome (P < .01) and higher periprocedural complications (P < .001) following iliac stent revascularization. Pattern type classification helps identify patients at higher risk for cardiovascular morbidity and mortality. Ideal candidates for iliac stent placement are patients with pattern type 1 or 2 disease.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.